Avanir Pharmaceuticals, Inc. (Nasdaq: AVNR) announced that data from its CNS therapeutics franchise, specifically in its pseudobulbar affect (PBA) and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE